PMID- 29494563
OWN - NLM
STAT- MEDLINE
DCOM- 20180827
LR  - 20240314
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 19
IP  - 3
DP  - 2018 Mar 1
TI  - Graphene Oxide-Silver Nanocomposite Enhances Cytotoxic and Apoptotic Potential of 
      Salinomycin in Human Ovarian Cancer Stem Cells (OvCSCs): A Novel Approach for 
      Cancer Therapy.
LID - 10.3390/ijms19030710 [doi]
LID - 710
AB  - The use of graphene to target and eliminate cancer stem cells (CSCs) is an 
      alternative approach to conventional chemotherapy. We show the 
      biomolecule-mediated synthesis of reduced graphene oxide-silver nanoparticle 
      nanocomposites (rGO-Ag) using R-phycoerythrin (RPE); the resulting RPE-rGO-Ag was 
      evaluated in human ovarian cancer cells and ovarian cancer stem cells (OvCSCs). 
      The synthesized RPE-rGO-Ag nanocomposite (referred to as rGO-Ag) was 
      characterized using various analytical techniques. rGO-Ag showed significant 
      toxicity towards both ovarian cancer cells and OvCSCs. After 3 weeks of 
      incubating OvCSCs with rGO-Ag, the number of A2780 and ALDH(+)CD133(+) colonies was 
      significantly reduced. rGO-Ag was toxic to OvCSCs and reduced cell viability by 
      mediating the generation of reactive oxygen species, leakage of lactate 
      dehydrogenase, reduced mitochondrial membrane potential, and enhanced expression 
      of apoptotic genes, leading to mitochondrial dysfunction and possibly triggering 
      apoptosis. rGO-Ag showed significant cytotoxic potential towards highly 
      tumorigenic ALDH(+)CD133(+) cells. The combination of rGO-Ag and salinomycin induced 
      5-fold higher levels of apoptosis than each treatment alone. A combination of 
      rGO-Ag and salinomycin at very low concentrations may be suitable for selectively 
      killing OvCSCs and sensitizing tumor cells. rGO-Ag may be a novel 
      nano-therapeutic molecule for specific targeting of highly tumorigenic 
      ALDH(+)CD133(+) cells and eliminating CSCs. This study highlights the potential for 
      targeted therapy of tumor-initiating cells.
FAU - Choi, Yun-Jung
AU  - Choi YJ
AD  - Department of Stem Cell and Regenerative Biotechnology, Konkuk University, Seoul 
      05029, Korea. choi_yunjung@naver.com.
FAU - Gurunathan, Sangiliyandi
AU  - Gurunathan S
AD  - Department of Stem Cell and Regenerative Biotechnology, Konkuk University, Seoul 
      05029, Korea. sangiliyandi@konkuk.ac.kr.
FAU - Kim, Jin-Hoi
AU  - Kim JH
AUID- ORCID: 0000-0003-1232-5307
AD  - Department of Stem Cell and Regenerative Biotechnology, Konkuk University, Seoul 
      05029, Korea. jhkim541@konkuk.ac.kr.
LA  - eng
PT  - Journal Article
DEP - 20180301
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Apoptosis Regulatory Proteins)
RN  - 0 (Biomarkers)
RN  - 0 (Oxides)
RN  - 0 (Pyrans)
RN  - 0 (Reactive Oxygen Species)
RN  - 3M4G523W1G (Silver)
RN  - 62UXS86T64 (salinomycin)
RN  - 7782-42-5 (Graphite)
SB  - IM
MH  - Antineoplastic Agents/chemistry/*pharmacology
MH  - Apoptosis/*drug effects
MH  - Apoptosis Regulatory Proteins/genetics/metabolism
MH  - Biomarkers
MH  - Cell Line, Tumor
MH  - Cell Survival/drug effects
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Gene Expression Regulation, Neoplastic/drug effects
MH  - *Graphite/chemistry
MH  - Humans
MH  - Immunophenotyping
MH  - Membrane Potential, Mitochondrial/drug effects
MH  - *Metal Nanoparticles/chemistry/ultrastructure
MH  - Models, Biological
MH  - Neoplastic Stem Cells/*drug effects/metabolism
MH  - Ovarian Neoplasms
MH  - *Oxides/chemistry
MH  - Pyrans/chemistry/*pharmacology
MH  - Reactive Oxygen Species/metabolism
MH  - *Silver/chemistry
MH  - Tumor Stem Cell Assay
PMC - PMC5877571
OTO - NOTNLM
OT  - apoptosis
OT  - cytotoxicity
OT  - human ovarian cancer cells
OT  - ovarian cancer stem cells (OvCSCs)
OT  - reduced graphene oxide-silver nanocomposite (rGO-Ag)
COIS- The authors declare no conflict of interest.
EDAT- 2018/03/02 06:00
MHDA- 2018/08/28 06:00
PMCR- 2018/03/01
CRDT- 2018/03/02 06:00
PHST- 2018/02/01 00:00 [received]
PHST- 2018/02/22 00:00 [revised]
PHST- 2018/02/26 00:00 [accepted]
PHST- 2018/03/02 06:00 [entrez]
PHST- 2018/03/02 06:00 [pubmed]
PHST- 2018/08/28 06:00 [medline]
PHST- 2018/03/01 00:00 [pmc-release]
AID - ijms19030710 [pii]
AID - ijms-19-00710 [pii]
AID - 10.3390/ijms19030710 [doi]
PST - epublish
SO  - Int J Mol Sci. 2018 Mar 1;19(3):710. doi: 10.3390/ijms19030710.